Targeted drugs can prolong the survival of patients with advanced lung cancer September 16, 2014 Source: Health News The team led by Prof. Zhou Caicun, director of the Cancer Research Institute of Tongji University School of Medicine and director of the Oncology Department of Shanghai Pulmonary Hospital, confirmed for the first time with evidence-based medical evidence from China that targeted drugs (erlotinib) are used in the first-line treatment of advanced epidermal growth factor in China. Patients with EGFR mutations in non-small cell lung cancer have good efficacy and safety, and can maximize the patient's progression-free survival by a factor of three while avoiding “blind treatmentâ€. The reporter recently obtained the above information from the International Lung Cancer Research Association and the Shanghai International Pulmonary Hospital in Shanghai. The OPTIMAL study conducted by Zhou Caicun's research team showed that in non-selective Chinese patients with non-small cell lung cancer, the total mutation rate of epidermal growth factor receptor ( EGFR ) was about 30.1%, and the mutation rate of adenocarcinoma patients was about 50%. Cancer patients can be as high as 60% to 70%, and squamous cell carcinoma patients also have 10% EGFR-sensitive mutation rate. The study also found that patients with EGFR gene-sensitive mutations were 70% to 80% more likely to use EGFR inhibitor erlotinib than patients without EGFR gene-sensitive mutations. The study also concluded that lung cancer targeted drug therapy is more effective for Asians, including China, than Westerners (Caucasian). The OPTIMAL study also found that patients who received chemotherapy alone had a total survival of 11.7 months, and those who received targeted therapy had a survival time of 20.67 months. The patients who used both targeted and chemotherapy lived the longest, reaching 30.39. Months. Vacuum packed Shelled shrimps,Vacuum packed shrimps,Fast Food Dried Shrimps Zhejiang ocean family co.,ltd , https://www.ocean-family.com